Brain with glowing pathways, symbolizing hope in glioblastoma treatment

Hope on the Horizon: A New Device Offers a Glimmer of Hope for Recurrent Glioblastoma Patients

Jordan Keane in Health & Wellness December 2025 • 4 min read.

"Early studies suggest the Nativis Voyager device may offer a safe and feasible treatment option for those battling this aggressive brain cancer."

Glioblastoma (GBM) is one of the most aggressive forms of brain cancer, often defying conventional treatments. When GBM returns after initial therapy, known as recurrent glioblastoma (rGBM), the challenges multiply. The prognosis for these patients is often poor, with limited treatment options available.

In the face of such adversity, the medical community continues to seek innovative solutions. A recent study published in CNS Oncology explores the potential of the Nativis Voyager device as a novel approach to treating rGBM. This device delivers ultra-low radio frequency energy (u/RFE®) to disrupt cancer cell growth.

This article breaks down the findings of this early feasibility study, offering a clear and accessible explanation of the Voyager device, its potential benefits, and what this research means for patients and their families facing the daunting reality of recurrent glioblastoma.

How Does the Nativis Voyager Device Work?

Brain with glowing pathways, symbolizing hope in glioblastoma treatment

The Nativis Voyager device is designed as a non-invasive, portable system that delivers ultra-low radio frequency energy (u/RFE®). Unlike traditional radiation therapy, u/RFE® is non-thermal and non-ionizing, meaning it doesn't generate heat or directly damage DNA. Instead, it uses a specific magnetic field to penetrate tissues and potentially alter biological functions within cells.

The core idea behind the Voyager device is to disrupt the rapid and uncontrolled cell division that characterizes cancer. The u/RFE® targets tubulin, a protein crucial for forming microtubules that separate chromosomes during cell division. By interfering with tubulin function, the device aims to hinder cancer cell proliferation.

Here's a breakdown of the device's key components:

Controller: A battery-operated unit that generates and regulates the u/RFE®.
Electromagnetic Coil: Worn externally on the head, this coil delivers the u/RFE® to the targeted area.
Battery Charger: Ensures continuous operation with a dual-controller setup.

The device is designed for ease of use, allowing patients to maintain their daily routines without significant disruption. This portability and non-invasive nature are key advantages, offering a more manageable treatment experience.

A Promising Step Forward

While still in early stages, the findings surrounding the Nativis Voyager device offer a beacon of hope for individuals and families grappling with recurrent glioblastoma. The device's safety profile and potential to stabilize disease progression mark a significant step forward in the ongoing quest for more effective and less invasive cancer treatments. Further research is essential to fully unlock the potential of u/RFE® therapy and refine its application in the fight against this challenging disease. Treatment options are evolving, so be sure to consult with a neuro-oncologist about potential treatment options.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is recurrent glioblastoma (rGBM), and why is it such a difficult condition to treat?

Glioblastoma (GBM) is a very aggressive type of brain cancer. What makes it particularly challenging is that it often resists standard treatments. When the cancer returns after initial treatment, it is then called recurrent glioblastoma (rGBM). This recurrence presents even more difficulties because treatment options are limited and the prognosis is generally poor.

Why is the Nativis Voyager device being studied for recurrent glioblastoma (rGBM)?

The Nativis Voyager device is significant because it offers a novel approach to treating recurrent glioblastoma (rGBM), a condition with limited effective treatment options. It uses ultra-low radio frequency energy (u/RFE®) to disrupt cancer cell growth. This is important because it provides a potentially safer and more manageable treatment experience for patients.

Can you explain how the Nativis Voyager device actually works to target cancer cells?

The Nativis Voyager device works by delivering ultra-low radio frequency energy (u/RFE®) to the targeted area. This energy is non-thermal and non-ionizing, meaning it doesn't generate heat or directly damage DNA. Instead, it uses a specific magnetic field to penetrate tissues and potentially alter biological functions within cells, disrupting the rapid and uncontrolled cell division that characterizes cancer.

What is ultra-low radio frequency energy (u/RFE®), and how does it affect cancer cells?

Ultra-low radio frequency energy (u/RFE®) targets tubulin, which is a protein crucial for forming microtubules. Microtubules are essential for separating chromosomes during cell division. By interfering with tubulin function, u/RFE® aims to hinder the proliferation of cancer cells. Unlike traditional radiation therapy, u/RFE® is non-thermal and non-ionizing, meaning it does not generate heat or directly damage DNA.

What are the main components of the Nativis Voyager device, and how do they work together?

The Nativis Voyager device consists of three main components. The Controller is a battery-operated unit that generates and regulates the ultra-low radio frequency energy (u/RFE®). The Electromagnetic Coil, worn externally on the head, delivers the u/RFE® to the targeted area. Lastly, the Battery Charger ensures continuous operation with a dual-controller setup, making the device portable and allowing patients to maintain their daily routines.